Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach-Reference-Cited by-同舟云学术

Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach

Published:2022-01-08 Issue:2 Volume:89 Page:197-208
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Reda Manon,Macaire Pauline,Bellio Hélène,Uwer Lionel,Ilie Silvia,Lorgis Véronique,Hennequin Audrey,Ladoire Sylvain,Rederstorff Emilie,Fumoleau Pierre,Isambert Nicolas,Bonnin Nathalie,You Benoit,Freyer Gilles,Desmoulins Isabelle,Schmitt Antonin^ORCID

Funder

Eisai

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00280-021-04395-y.pdf

Reference24 articles.

1. Swami U, Chaudhary I, Ghalib MH et al (2012) Eribulin—a review of preclinical and clinical studies. Crit Rev Oncol Hematol 81:163–184

2. Cortes J, O’Shaughnessy J, Loesch D et al (2011) Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377:914–923

3. Kikuchi Y, Uchida Y, Shirakawa K et al (2018) A multicenter, observational study of metastatic breast cancer patients who were treated with eribulin mesylate or taxane-based regimens. Asia Pac J Clin Oncol 14:e231–e237

4. Kimura K, Iwamoto M, Tanaka S et al (2018) A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes. Cancer Chemother Pharmacol 81:923–933

5. Sabatier R, Diéras V, Pivot X et al (2018) Safety results and analysis of eribulin efficacy according to previous microtubules-inhibitors sensitivity in the French prospective expanded access program for heavily pre-treated metastatic breast cancer. Cancer Res Treat 50:1226–1237

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Semimechanistic pharmacokinetic–pharmacodynamic model of tripegfilgrastim for pediatric patients after chemotherapy;CPT: Pharmacometrics & Systems Pharmacology;2023-08-09